“We do not plan for that with Orforglipron. So we will plan to launch or submit and have approvals and then launch in a full sense, including activities you're used to seeing for primary care products like sampling, co-pay, full formulary access and globalization of Orforglipron as rapidly as possible.”

In context

“istance programs and the implementation of channel tools like Lilly Direct, should all those be at the outset? Mike Czapar: Thanks, Chris, for the very detailed question. We'll go to Dave to talk a bit about the Orforglipron launch prep. David Ricks: Okay. Yes. Look, the goal here with Orforglipron because it's using different production systems that are available to us. It's a long cycle of processing to get commercial product, but it's very predictable, and we have access to those platforms inside and outside the company. So we are building for a full launch in the normal pharma sense. And here, pointing out maybe the flip of the earlier question about demand, we have had to gate all these things to make sure we carefully match supply and demand for the injectables as is our competitor. We do not plan for that with Orforglipron. So we will plan to launch or submit and have approvals and then launch in a full sense, including activities you're used to seeing for primary care products like sampling, co-pay, full formulary access and globalization of Orforglipron as rapidly as possible. And we're building capacities to do that. And hopefully, that will begin in early '26. I think as Dan mentioned, the first complete package for submission in the U.S. will be obesity. But we expect diabetes to shortly follow and then these other indications that have been discussed today. I hope that answers the question. Operator: The next question will be from James Shin from Deutsche Bank. James Shin: Another one for Dan on Orforglipron. I appreciate the earlier comments on indexing Orforglipron's efficacy to semaglutide and the Phase III titration schedule. But can you go over how this titration schedule may impact the Phase II weight loss, A1c and safety results published in Lancet and New England Journal? David Ricks: Great. Thanks, Seamus, for the question. We'll go to Dan to talk”